Pre-earnings options volume in Lexicon (LXRX) Pharmaceuticals is normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 14.8%, or 18c, after results are released. Median move over the past eight quarters is 11.5%.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- Lexicon announces JASN publishes sotagliflozin data
- Lexicon to present data from two studies related to LX9851
- LXRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Lexicon price target lowered to $6 from $10 at H.C. Wainwright
- FDA panel votes 11-3 that Lexicon’s Zynquista benefits do not outweigh risks